

# From 2D to 3D



# 3D planning in breast cancer


Prof Ramesh S Bilimagga

President- AROI

Medical Director - HCG

# Road map of the talk

- Should we change from 2D to 3D planning
- What are its advantages
- Review of literature
- How do we do it? – Steps
- Types of 3D planning
- Conclusion




Should we change to 3D planning

**YES?**


# Indications

- Following neo-adjuvant chemotherapy
- As a part of Breast conservation therapy.
- Post mastectomy RT
  1. Positive nodes:  $>4$  ; (?)1-3
  2. Large tumors: T<sub>3</sub> +
  3. Skin involvement






# What are its advantages

- **Dosimetry**
  - Better Dose Homogeneity
  - Better Dose Conformality
  - SIB – Feasible
- **Clinical**
  - Dose to Heart & Lung can be minimized.
  - Better Cosmetic Outcome ?





2D


IMRT



# Cardiac injury in breast RT




Nilsson et al JCO 2011





# Review of Literature

- William Beaumont Hospital
- Ontario Phase 3 Multicenter trial
- Royal Marsden Hospital



# William Beaumont Hospital

## 2D (wedges) vs IMRT

- N = 172, CT plan,
  - 1.8 Gy X25
- + 2 GyX 8 photons.

Toxicity	IMRT (%)	Wedges	p
<b>Acute Grade &gt;2</b>			
<b>Dermatitis</b>	<b>41</b>	<b>85</b>	<b>&lt;0.001</b>
<b>Breast edema</b>	<b>1</b>	<b>28</b>	<b>&lt;0.001</b>
Pain	8	8	0.78
<b>Hyperpigmentation</b>	<b>5</b>	<b>50</b>	<b>&lt;0.001</b>
<b>Chronic Grade &gt;2</b>			
Hyperpigmentation	7	17	0.06
<b>Breast edema</b>	<b>1</b>	<b>25</b>	<b>&lt;0.001</b>
Fat Necrosis	0	1	0.46
Induration/fibrosis	0	6	0.11
Good/excellent fibrosis	99	97	0.60

Harsolia et al. IJROBP 68-5  
(2007)

# Ontario phase III multicentre trial

## 2D (wedges) vs 3D IMRT

- N = 331, CT plan
  - 2GyX 25
- +2 Gy x 8 elec.

Toxicity	IMRT (%)	Wedges	p
Skin Toxicity 3-4	27.1	36.7	0.06
Moist desquamation, all breast	31.2	47.8	0.002
Moist desquamation, Inframammary crease	26.5	43.5	0.001
Pain grade 2-4	26.5	25.5	0.68

Grading NCI CTC 2.0

# Royal Marsden phase III randomised trial

## 2D (wedges) vs 3D IMRT

- N= 240
- Single contour plan
- 25x2 Gy+5x2Gy electrons.
- Reduced late effects
  - change in breast appearance from 58% to 40%
  - Reduction of induration

Toxicity	STD	IMRT (%)	p
	Year 5 Assessment		
Center of the breast	37/117(32%)	25/118(21%)	0.02
Pectoral fold	34/118 (29%)	26/119 (22%)	0.006
Inframammary Fold	28/116 (24%)	20/117(17%)	0.009
Boost site	70/114(61%)	43/115(61%)	<0.001

# RCT Analysis – FIMRT in EBC

- 1145 – trial plans
- Standard plans Vs FIMRT plans

	FIMRT	2D	p value
V>107% & V<95%	34cm <sup>3</sup> (26.4-41.6)	48.1 cm <sup>3</sup> (34.4-61.9)	<0.0001

- Confirmed FIMRT improved breast dosimetry
- More likely dosimetric benefit – large breasts

# IMRT for BCT


## Cosmesis:

	Physician	Patient
Excellent	63%	33%
Good	33%	50%
Fair/Poor	<1.5%	17%


## Predictors :

1. Increased Boost volume
2. Breast tumor ratio
3. Erythema
4. Telangiectasia

Kelle et al IJROBP 2012



# Steps



Patient positioning



Volumetric Data acquisition






Image Transfer to the TPS




Target Volume Delineation



Treatment QA




Treatment Delivery



Dose distribution Analysis

Forward Planning

Inverse Planning



3D Model generation

# Physics of FIMRT

## CT based

- 75% of dose with open fields
- 8 extra segments
- Min. segment size 9 cm<sup>2</sup>
- Simple planning objectives


## Additional benefits

- Less MU, less scatter
- Decreased planning time
- Decreased beam-on time
- Less susceptible to breast deformations.



# Breast Contouring

- Breast Contour
  - Consider referred clinical breast at time of CT
  - Includes the apparent CT glandular breast tissue
  - Incorporates consensus definitions of anatomical borders
  - Includes the lumpectomy CTV
- Lumpectomy CTV
  - Includes seroma & surgical clips where present



# Breast CTV

- The target volume must include all the total glandular breast tissue
- Borders are not clearly visible
- Radio opaque wire around the breast tissue to help guide the approx borders of breast tissue (do not represent the true borders)




# Breast Contour – Anatomical Boundaries



Cranial	Caudal	Anterior	Posterior	Lateral	Medial
Clinical Reference + Second rib insertion	Clinical reference + loss of CT apparent breast	Skin	Excludes pectoralis muscles, chestwall muscles, ribs	Clinical Reference + mid axillary line typically, excludes latissimus (Lat.) dorsum	Sternal-rib junction



■ Lumpectomy  
■ Breast  
■ Heart





Lumpectomy  
Breast  
Heart



# Chest wall delineation

- All borders of the CTV thoracic wall are usually considered to be identical to the CTV breast
- In post MRM radio opaque wires should be positioned around the imaginary original site of the breast & on the scar
- Careful palpation of the thoracic wall & the position of the mastectomy scar should be used well.




# CHEST Wall - special

- Most cases the tissue upto the skin is removed and skin is adherent to the thoracic wall.
- Use bolus in such cases to deliver dose to the skin and the thoracic wall.



# Chest wall contour-Anatomical Boundaries

Cranial	Caudal	Anterior	Posterior	Lateral	Medial
Caudal border of the clavicle head	Clinical reference+ loss of CT apparent contralateral breast	Skin	Rib-pleural interface. (Includes pectoralis muscles, chestwall muscles, ribs)	Clinical Reference/ mid axillary line typically, excludes lattismus dorsi m.	Sternal - rib junction





Supraclavicular




Axilla level 3

Axilla level 2

Axilla level 1

Chestwall

Heart





Supraclavicular



Axilla level 3



Axilla level 2

Axilla level 1

Unestwall

Heart





Supraclavicular


Axilla level 3


Axilla level 2

Axilla level 1

Chestwall

Heart





Supraclavicular


Axilla level 3

Axilla level 2

Axilla level 1

Chestwall

Heart



# Types of IMRT






- FIMRT

- Beams parameters specified / manually changed as reqd.
- Dose distribution computed
- Manual iterations
- Time consuming
- Subjective function






- Inverse IMRT

- Dose distribution specified
- Computerised beam parameters
- Auto iterations
- Quicker
- Objective function






# Forward plan IMRT



# Medial Tangential Segments




# Lateral Tangential Segments






# Plan Evaluation

- Target coverage
- Homogeneity of dose distribution
- Dose distribution on all slices
- Dose to organs at risk
  1. Opposite breast
  2. Lungs : Ipsilateral and combined
  3. Heart : Especially in Left sided




# Plan goals


PTV	
V95	$\geq 95\%$
V107	$< 2\%$ or 2 cc
Lung V 20 Gy	$< 15\%$
Heart V 50	$\leq 1$ cc



Open fields




F IMRT




# Prone IMRT at MSKCC

- Minimize radiation to the heart and lungs by utilizing gravity effect on mobile breast
- Specify beam direction (Two tangent fields) before inverse planning process to avoid an increase in integral dose
- Bring dose intensity pattern to field edge to account for minimal edema through treatment.





Breast board



Patient in Position




CT scan



# Conclusion

- Reduce Acute Toxicity
- Late effects – Data Awaited
- No increased survival benefit
- IMRT feasible for Intact Breast





**Bengaluru welcomes you to**

# **2nd Indian Cancer Congress 2017**

